Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nicolo Cabrera"'
Autor:
Frederick Berro Rivera, Marie Francesca Mapua Ansay, Jem Marie Golbin, Pia Gabrielle I. Alfonso, Gerard Francis E. Mangubat, Rajiv Hans Solita Menghrajani, Siena Placino, Marianne Katharina Vicera Taliño, Deogracias Villa De Luna, Nicolo Cabrera, Carlo Nemesio Trinidad, Amir Kazory
Publikováno v:
Glomerular Diseases, Pp 1-11 (2022)
Background: HIV-associated nephropathy (HIVAN) is a renal parenchymal disease that occurs exclusively in people living with HIV. It is a serious kidney condition that may possibly lead to end-stage kidney disease, particularly in the HIV-1 seropositi
Externí odkaz:
https://doaj.org/article/612a26ca24ee4d16ae12b532dcd31032
Publikováno v:
BMJ Global Health, Vol 7, Iss 10 (2022)
Externí odkaz:
https://doaj.org/article/5a6fb86032474cedad608f83340d47d9
Publikováno v:
BMJ Global Health. 7:e010630
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::923656c77209d80ba2b2233740e030d0
https://doi.org/10.1136/bmjgh-2022-010630
https://doi.org/10.1136/bmjgh-2022-010630
Autor:
Nicolo Cabrera, Truc T Tran, Travis J Carlson, Faris Alnezary, William R Miller, An Q Dinh, Blake Hanson, Jose Munita, Samuel A Shelburne, Samuel L Aitken, Kevin W Garey, Laura A Puzniak, Cesar A Arias
Publikováno v:
Open Forum Infectious Diseases
Background Ceftolozane/tazobactam (C/T) is a novel cephalosporin/beta-lactamase inhibitor combination developed for use against multidrug-resistant (MDR) Gram-negative infections, particularly Pseudomonas aeruginosa (PA). C/T is approved for complica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aafa1ec006e10ea3994fce61402c0e2
http://europepmc.org/articles/PMC7777747
http://europepmc.org/articles/PMC7777747
2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
Autor:
Nicolo Cabrera, Truc T Tran, William R Miller, An Q Dinh, Blake Hanson, Jose M Munita, Samuel A Shelburne, Samuel L Aitken, Kevin W Garey, Laura A Puzniak, Cesar A Arias
Publikováno v:
Open Forum Infectious Diseases
Background Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination for treating Gram-negative infections, particularly Pseudomonas aeruginosa (PA). C/T has been FDA-approved for complicated intra-abdominal and urinary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7225d0a1953c463e748c0d9e0969ab13
https://doi.org/10.1093/ofid/ofz360.1926
https://doi.org/10.1093/ofid/ofz360.1926
Autor:
Nicolo Cabrera, Gregory Huhn, Kerianne Burke, Crystal Winston, Benjamin Go, Oluwatoyin Adeyemi
Publikováno v:
Open Forum Infectious Diseases
Background Despite guidelines recommending liver ultrasound (US) every 6 months for HCC screening in cirrhotic patients with HCV, reported screening rates remain low. Our study evaluated (1) timely screening among patients with HCV cirrhosis identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7608d08e4426f59d085b4aef36b49f
http://europepmc.org/articles/PMC5632172
http://europepmc.org/articles/PMC5632172